Real-world data lipid profiles in one million colombian adults: The LiPAC million person study.

Autor:	Colmenares-Mejía CC; Fundación Universitaria Sanitas. Grupo de investigación INPAC. Grupo Keralty. Bogotá, Colombia., Godoy-Corredor M; Laboratorio Clínico y de Patología, Clínica Colsanitas. Grupo Keralty. Bogotá, Colombia., Morales-Mendoza E; Fundación Universitaria Sanitas. Grupo de investigación Gerencia y Gestión Sanitaria. Grupo Keralty. Bogotá, Colombia., Pinto-Pinzón DA; Fundación Universitaria Sanitas. Coordinación Posgrado Medicina Interna. Grupo Keralty. Bogotá, Colombia.; Servicio de Medicina Interna, Clínica Universitaria Colombia. Clínica Colsanitas. Grupo Keralty. Bogotá, Colombia., Rozo-Vanstrahlen JM; Servicio de Cardiología, Clínica Reina Sofía. Clínica Colsanitas. Grupo Keralty. Bogotá, Colombia., Acuña-Olmos J; Servicio de Cardiología, Clínica Reina Sofía. Clínica Colsanitas. Grupo Keralty. Bogotá, Colombia.; Fundación Universitaria Sanitas. Posgrado de Cardiología. Grupo Keralty. Bogotá, Colombia., Hilarión-Gaitán L; Fundación Universitaria Sanitas. Grupo de investigación INPAC. Grupo Keralty. Bogotá, Colombia., Suarez-Ramos MDP; Laboratorio Clínico y de Patología, Clínica Colsanitas. Grupo Keralty. Bogotá, Colombia., Ruiz-Amaya DA; Laboratorio Clínico y de Patología, Clínica Colsanitas. Grupo Keralty. Bogotá, Colombia., Salazar-Heredia FR; Laboratorio Clínico y de Patología, Clínica Colsanitas. Grupo Keralty. Bogotá, Colombia., Vargas-Rodríguez J; Laboratorio Clínico y de Patología, Clínica Colsanitas. Grupo Keralty. Bogotá, Colombia., Isaza-Ruget MA; Fundación Universitaria Sanitas. Grupo de investigación INPAC. Grupo Keralty. Bogotá, Colombia.; Laboratorio Clínico y de Patología, Clínica Colsanitas. Grupo Keralty. Bogotá, Colombia.
Jazyk:	angličtina
Zdroj:	Atherosclerosis plus [Atheroscler Plus] 2024 Nov 16; Vol. 58, pp. 51-58. Date of Electronic Publication: 2024 Nov 16 (Print Publication: 2024).
DOI:	10.1016/j.athplu.2024.11.001
Abstrakt:	Background and Aims: Lipid profile results are of clinical interest for assessing the presence of dyslipidemia and the risk of cardiovascular disease. This study aimed to characterize lipid profile parameters in a large adult population from different regions of Colombia. Methods: Cross-sectional study. Adults with a complete lipid profile [TC, c-HDL, non-c-HDL, c-LDL, Triglycerides] from a national reference laboratory between 2018 and 2022 were included. Lipid profile levels are reported as medians and adjusted means and are also presented according to different guideline thresholds. Mixed dyslipidemia frequencies are also reported. Results: 1,030,195 subjects were included, with a median age of 49 years (IQR 36-61 years); 59.8 % were females. Adjusted mean value for TC was 188.1 mg/dl (CI95 % 188.0-188.2), 110.1 mg/dl (CI95 % 110.0-110.1) for c-LDL, 45.9 mg/dl (CI95 % 45.9-46.0) for c-HDL, 139.1 mg/dl (CI95 % 139.0-139.2) for non-c-HDL and 129.5 mg/dl (CI95 % 129.4-129.6) for triglycerides. The most frequent single dyslipidemia was c-HDL <40 mg/dL (n = 86,725, 8.4 %), and the most common mixed dyslipidemia was TC ≥ 200 mg/dL + c-LDL >130 mg/dL (n = 138,366, 17.0 %). Elevated c-LDL (≥130 mg/dL) was found in 32.4 % of the population, while c-LDL levels ≥190 mg/dL were observed in 2.0 % (n = 21,045). Triglyceride levels ≥500 mg/dL were identified in 0.3 % (n = 3103). Conclusion: This large study on lipid markers from a selected sample of Colombian adults' highlights variations in dyslipidemia by gender, age, and region. The findings emphasize the need for targeted interventions to reduce cardiovascular risk. Identifying high-risk groups is essential to improving outcomes in developing countries. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: LHG reports financial support for consulting or advisory provided by 10.13039/100004337Roche Diagnostic Colombia. 10.13039/100018675MGC, 10.13039/501100012169MPSR, DARA, FRSH, JVR, MAIR reports administrative support provided by 10.13039/100004337Roche Diagnostic Colombia. DAPP reports financial support for speaking and lecture fees provided by 10.13039/100002429Amgen Inc, 10.13039/100001316Abbott Laboratories, 10.13039/100007659Bayer Corporation, 10.13039/100008272Novartis Pharmaceuticals Corporation. Remain authors declare that there is no conflict of interests regarding the publication of this paper. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu